The duration of the treatment's effect varies among individuals. However, our preliminary data suggests that the benefits can last for several years. We continue to monitor and study the long-term effects to provide more accurate estimates.

We are committed to making our treatment affordable and accessible. The final cost will be determined closer to the product launch, taking into consideration factors like production costs and market demand. Familiarity of local cuisines, language barriers, and limited access to lactose-free options can make vacations stressful and less enjoyable.

Our gene therapy utilizes Adeno-Associated Viruses (AAVs) to transfer a DNA plasmid into the nucleus of target cells in the small intestine. This process does not alter or integrate into your existing genome. Instead, it provides the cells with the necessary genetic information to address lactose intolerance without changing your overall genetic makeup.

No. The therapy modifies somatic cells (non-reproductive cells) and does not affect your reproductive cells or DNA. Therefore, any genetic modifications will not be inherited by your children.

We are making significant progress in our research and development. While we cannot provide an exact date, we aim to have our product available within the next few years, pending regulatory approvals.

Once approved, our treatment will be available through licensed healthcare providers. We will provide more details on purchasing and distribution closer to the product launch.